Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of AL003 in Healthy Participants and Participants With Alzheimer's Disease
NCT03822208Phase 1Completed
- Sponsor
- Alector
- Start
- Mar 2019
- Primary completion
- May 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing AL003 with Placebo (2 arms). Primary endpoint: Number of subjects with adverse events and dose limiting adverse events (DLAE) at 141 days. Started Mar 2019; status: completed.
02
Drugs
AL003
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03822208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822208.